Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | PPM1B | O75688 | 1/20 | 0.44 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.44 |
| ▸ | PPP1CC | P36873 | 1/20 | 0.44 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.42 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.42 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.42 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.42 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | MMP2 | P08253 | 1/20 | 0.40 |
| ▸ | ANPEP | P15144 | 1/20 | 0.40 |
| ▸ | BRD4 | O60885 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL363035 | 1.00 | TP53 (0.47) | TP53SMN1; SMN2PPM1BPTPN1PPP1CC | |
| SCHEMBL380500 | 1.00 | TP53 (0.47) | TP53SMN1; SMN2PPM1BPTPN1PPP1CC | |
| Hydrochloric Acid SCHEMBL363034 | 0.98 | TP53 (0.46) | TP53SMN1; SMN2PPM1BPTPN1PPP1CC | |
| Hydrochloric Acid SCHEMBL363033 | 0.98 | TP53 (0.46) | TP53SMN1; SMN2PPM1BPTPN1PPP1CC | |
| Hydrochloric Acid SCHEMBL1178819 | 0.98 | TP53 (0.46) | TP53SMN1; SMN2PPM1BPTPN1PPP1CC | |
| SCHEMBL24475220 | 0.92 | SMN1; SMN2 (0.47) | TP53SMN1; SMN2PPM1BPTPN1PPP1CC | |
| SCHEMBL22096230 | 0.92 | SMN1; SMN2 (0.51) | TP53SMN1; SMN2PPM1BPTPN1PPP1CC | |
| SCHEMBL19910371 | 0.90 | SMN1; SMN2 (0.54) | TP53SMN1; SMN2PPM1BPTPN1PPP1CC | |
| Sulfuric Acid SCHEMBL27596525 | 0.88 | TP53 (0.47) | TP53SMN1; SMN2PPM1BPTPN1PPP1CC | |
| SCHEMBL13245964 | 0.88 | TP53 (0.40) | TP53SMN1; SMN2PPM1BPTPN1PPP1CC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 344 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12616682-B2 | 1-H-pyrrolo[2,3-c]pyridine compounds | ACERTA PHARMA B.V. (NL) | 2026-05-05 | — | — | US | disclosed |
| EP-4724430-A1 | CONDENSED AZINES AS INHIBITORS OF CYCLIC ADP RIBOSE HYDROLASE | Flagship Pioneering Innovations VI, LLC (US) | 2026-04-15 | — | — | EP | disclosed |
| EP-4423075-B1 | CCR6 RECEPTOR MODULATORS | IDORSIA PHARMACEUTICALS LTD (CH) | 2026-03-25 | — | — | EP | disclosed |
| EP-4709720-A1 | INHIBITORS AND DEGRADERS OF PIP4K PROTEIN | Larkspur Biosciences, Inc. (US) | 2026-03-18 | — | — | EP | disclosed |
| US-20250360112-A1 | 1-H-PYRROLO[2,3-c]PYRIDINE COMPOUNDS | ACERTA PHARMA BV (NL) | 2025-11-27 | — | — | US | disclosed |
| EP-4620951-A1 | MEMANTINE UREA DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOF IN PREPARATION OF MEDICAMENT FOR TREATING SOLUBLE EPOXIDE ENZYME-MEDIATED DISEASES | Shenyang Pharmaceutical University (CN) | 2025-09-24 | — | — | EP | disclosed |
| EP-4608810-A1 | COMPOUNDS, COMPOSITIONS AND METHODS OF USE TO TREAT HYPOPARATHYROIDISM AND OSTEOPOROSIS | Septerna, Inc. (US) | 2025-09-03 | — | — | EP | disclosed |
| WO-2025059577-A1 | SUBSTITUTED AMINOPYRIDINE COMPOUNDS FOR USE AS AKT1 INHIBITORS | ATAVISTIK BIO, INC. (US) | 2025-03-20 | — | — | WO | disclosed |
| US-20250011313-A1 | CCR6 RECEPTOR MODULATORS | IDORSIA PHARMACEUTICALS LTD (CH) | 2025-01-09 | — | — | US | disclosed |
| WO-2024254396-A1 | CONDENSED AZINES AS INHIBITORS OF CYCLIC ADP RIBOSE HYDROLASE | FLAGSHIP PIONEERING INNOVATIONS, VI, LLC (US) | 2024-12-12 | — | — | WO | disclosed |
| US-5880284-A | HAVING ANTITHROMBOTIC, ANTIAGGREGATORY AND TUMOR- OR METASTASES-INHIBITING EFFECTS | DR. KARL THOMAE GMBH (DE) | 1999-03-09 | — | — | US | disclosed |
| US-5821240-A | ENZYME INHIBITORS, SIGNAL INHIBITORS FOR ANTIINFLAMMATORY AGENTS, ANTICARCINOGENIC AGENTS, ANTITUMOR AGENTS AND HORMONE INHIBITORS | DR. KARL THOMAE GMBH (DE) | 1998-10-13 | — | — | US | disclosed |
| US-5817677-A | ANTITHROMBOSIS AGENTS | DR. KARL THOMAE GMBH (DE) | 1998-10-06 | — | — | US | disclosed |
| US-5707989-A | ANTITUMOR AGENTS, INHIBITING SIGNAL TRANSDUCTION MEDIATED BY TYROSINE KINASES | DR. KARL THOMAE GMBH (DE) | 1998-01-13 | — | — | US | disclosed |
| US-5681841-A | PREVENTION CELL AGGREGATION | KARL THOMAE GMBH (DE) | 1997-10-28 | — | — | US | disclosed |
| US-5563268-A | FOR PREVENTING CELL AGGLOMERATION, TREATING THROMBOSIS, ARTERIOSCLEROSIS, BRAIN, LUNG OR CARDIOVASCULAR DISORDERS | DR. KARL THOMAE GMBH (DE) | 1996-10-08 | — | — | US | disclosed |
| US-5442064-A | Anticoagulants, antiagglomerants | DR. KARL THOMAE GMBH (DE) | 1995-08-15 | — | — | US | disclosed |
| US-5418233-A | FOR INHIBITING CELL AGGREGATION | KARL THOMAE GMBH (DE) | 1995-05-23 | — | — | US | disclosed |
| CN-1092769-A | Cyclic urea derivatives, the method that contains the pharmaceutical composition of these compounds and prepare them | THOMAE GMBH DR K (DE) | 1994-09-28 | — | — | CN | disclosed |
| CN-1087904-A | Carboxylic acid derivative, the pharmaceutical composition that contains these compounds with and preparation method thereof | KRAL THOMAE GMBH (DE) | 1994-06-15 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250011313-A1 | CCR6 RECEPTOR MODULATORS | CCR6, CCR1, CCR4 | TP53 3012/4885SMN1; SMN2 3217/4885PPM1B 2097/4885 |
| US-12616682-B2 | 1-H-pyrrolo[2,3-c]pyridine compounds | MEN1, PKD1, PKD2 | TP53 4094/4885SMN1; SMN2 121/4885PPM1B 689/4885 |
| US-20250360112-A1 | 1-H-PYRROLO[2,3-c]PYRIDINE COMPOUNDS | MEN1, PKD1, ADCYAP1R1 | TP53 1914/4885SMN1; SMN2 220/4885PPM1B 519/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.